Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases

Next Previous
Trial Profile

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CNTY-101 (Primary)
  • Indications Diffuse scleroderma; Lupus nephritis; Myositis; Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms CALiPSO-1; CALiPSO-1A
  • Sponsors Century Therapeutics

Most Recent Events

  • 15 May 2025 According to a Century Therapeutics media release, company remain on track to deliver clinical data for CNTY-101 by the end of 2025.
  • 15 May 2025 According to a Century Therapeutics media release, In Mar 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for patients with B-cell-mediated autoimmune diseases.
  • 14 May 2025 According to a Century Therapeutics media release, five clinical trial sites in the U.S. are active with additional U.S. clinical trial sites expected to open in 2025. Site activation activities are underway in select European countries, with enrollment at these sites expected to initiate in the second half of 2025. The Clinical Trial Application (CTA) has been authorized in Germany, France, and Italy,

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top